Leap Therapeutics, Inc. (LPTX)

USD 0.34

(5.25%)

Market Cap (In USD)

14.06 Million

Revenue (In USD)

-

Net Income (In USD)

-81.41 Million

Avg. Volume

2.63 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.68-5.0
PE
-0.19
EPS
-1.81
Beta Value
0.217
ISIN
US52187K2006
CUSIP
52187K101
CIK
1509745
Shares
41257600.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Douglas E. Onsi J.D.
Employee Count
-
Website
https://www.leaptx.com
Ipo Date
2017-01-25
Details
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.